Tag:

Actavis

Latest Headlines

Latest Headlines

Actavis asks court to let it stop manufacturing older Alzheimer's treatment

Actavis has made its case to a federal appeals court that it should be able to stop making the original version of its Alzheimer's treatment Namenda IR, which is going off patent, and replace it with its once-daily version Namenda XR.

Actavis says it'll lose $200M in Namenda sales if appeals court nixes a 'hard switch'

Actavis is trying to encourage an appeals court to let it force patients over to a new, patent-protected version of Alzheimer's treatment Namenda. Hundreds of millions in sales rest on the decision. But so far, the judges aren't offering any clues about their answer.

Allergan drops Valeant-Ackman insider trading lawsuit

Allergan--now owned by Actavis--and its former hostile suitors, Valeant and Bill Ackman's Pershing Square, are putting the past behind them.

Actavis, Ironwood mount second DTC push for GI med Linzess

With Actavis and Ironwood's first DTC campaign for GI med Linzess, the goal was to help patients identify irritable bowel syndrome with constipation and chronic idiopathic constipation by clearly communicating the symptoms. Now that the team is back with its sophomore DTC effort, the goal is to encourage patients to find a solution to their problems. A branded, prescription solution.

Actavis' drug delivery-focused spinoff on the prowl for acquisitions

The divestiture of Actavis' drug delivery unit to private equity firm TPG is now complete. The Irish pharma company divested Aptalis to focus on its recently completed merger with Allergan for $70 billion. John Fraher, the CEO of the new drug delivery company, dubbed Adare, told FierceDrugDelivery he intends to grow the company by acquisition.

Actavis execs up for $101M in merger-related bonuses, if investors approve

Through a storm of M&A activity, Actavis CEO Brent Saunders has climbed his way up into the CEO's chair at one of pharma's top 10 drugmakers--and it's a climb for which he's been well rewarded.

Actavis moves quickly to sell Australia generics business to Amneal

Actavis Australia has agreed to sell its generic pharmaceuticals business to Swiss-based Amneal Pharmaceuticals for an undisclosed amount, moving quickly to shed a unit that is not seen as core to the branded drug business after the merger with Allergan.

What's an Allergan career worth? $534M in cash, if you're ex-CEO David Pyott

Actavis' agreement to buy Allergan for $66 billion put then-Allergan CEO David Pyott in line for a hefty payout in cash and shares--and now that the tie-up is official, he's collecting.

Deals for Actavis, Teva plants put G&W in the spotlight; CEO says its culture is its beacon

G&W Laboratories, a small generic drugmaker, recently broke onto the pharma scene publicly with two substantial deals in 10 months for plants and products. The first deal was last summer when it bought an Actavis plant, and this month it announced a deal to do the same with Teva Pharmaceutical Industries.

Hedge fund patent challenges are growing by the numbers, and drugmakers aren't happy

Generics makers aren't the only ones filing challenges to pharma patents anymore. Hedge funds are doing it, too, and it's got drugmakers on edge.